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Bo Hu,1 Yan He,1 Yan Wu,1 Guangming Bao,1 Haiyan Liu,1,2 Lisbeth A. Welniak,3
William J. Murphy3Donor NK cells have been shown to be able to promote engraftment during allogeneic bone marrow
transplantation. They could specifically suppress or delete host reactive cells, thereby facilitating engraftment
of donor marrow. To further elucidate the mechanism, we showed that activated H2d ALAK cells (adherent
lymphokine activated killer, IL-2 activated T cell-depleted bone marrow and spleen cells) from BALB/c mice
significantly suppressed the proliferation of H2b splenocytes from C57BL/6 mice in mixed lymphocyte re-
sponses (MLR) stimulated with irradiated H2d splenocytes from BALB/c mice (P\ .01). The ability for
H2b splenocytes to kill H2d tumor targets was also significantly inhibited by activated H2d ALAK cells
(P\.01). The same number of H2b ALAK cells or H2d splenocytes did not show the same suppressive effect.
These results suggested that activated H2d ALAK cells could specifically suppress the anti-H2d activity of the
H2b splenocytes. Anti-tumor growth factor (TGF)b antibody blockade did not diminish this suppressive ef-
fect of ALAK cells, suggesting that this activity is not dependent on TGF-b secretion. ALAKs from gld (FasL
mutant) mice suppressed the allo-responses as well as the wild-type ALAK cells. The ALAKs from pfp (per-
forin knockout) mice did not completely block the inhibitory effect, which suggested that the suppressive
effect of the allogeneic ALAK cells could be partially caused by perforin-mediated killing. We further dem-
onstrated that donor ALAK cells could promote engraftment by suppressing host alloreactive responses in
a nonmyeloablative allogeneic BMT model. These studies suggest that activated donor NK cells specifically
suppress the alloreactive cells and provide a promising way to promote donor engraftment without involving
systemic and nonspecific suppression of the immune system.
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Allogeneic bone marrow transplantation (BMT)
has revolutionized the treatment of leukemia, lym-
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6/j.bbmt.2010.02.023BMT, a patient will receive a conditioning regimen
that can either bemyeloablative or of reduced intensity
consisting of less cytoreductive conditioning but
involves more extensive immunosuppression treat-
ments [1,2]. However, despite immunosuppression,
marrow rejection by host effector cells remains
a significant concern. It would be extremely desirable
to develop means to promote donor engraftment that
do not involve extensive, systemic, and nonspecific
suppression of the immune system.
Natural killer (NK) cells represent a key component
of the innate immune system and can mediate MHC
unrestricted cytotoxicity against neoplastic and virally
infected cells; they can also secrete numerous effector
cytokines [3,4]. NK cells can mediate rejection of
bone marrow but not solid-tissue allografts [5]. How-
ever, NK alloreactivity in the opposite direction, that
is, donor-versus-recipient, have the potential to
improve engraftment of mismatched transplants. In
mice, the pretransplant infusion of donor alloreactive
NK cells was successfully combined with reduced-
intensity conditioning (RIC) to achieve durable full
donor engraftment [6]. It was also shown that donor
Biol Blood Marrow Transplant 16:772-781, 2010 773Allogeneic NK Cells as Suppressors of Allo-responsesNK cells can contribute to the antitumor effect [7,8].
Therefore, we hypothesize that transfer of donor NK
cells may result in specific suppression or deletion of
host alloreactive cells, thereby facilitating engraftment
of donor marrow.
In mice, we postulate that donor NK cells, being
activated in vitro with IL-2, would promote engraft-
ment by the mechanism in which host alloreactive cells
upon interacting with the activated donor NK cells,
would then be either deleted by donor NK killing or
suppressed by tumor growth factor (TGF)-b, pro-
duced by the activated NK cells. It has been shown
that NK cells could have veto activity against cytotoxic
T cell precursors, which may suppress the alloreactiv-
ity from the host bone marrow [9]. ‘‘Veto activity’’ was
defined in 1980 by Miller as the capacity to specifically
suppress cytotoxic T cell (CTL) precursors directed
against antigens of the veto cells themselves, but not
against third party antigens [10-13]. It has been
shown that the suppression by the veto activity is
mediated by apoptosis [14,15]. Apoptosis can be
induced by cytotoxic granule release (granzyme and
perforin mediated killing), Fas-FasL mediated killing,
or release of apoptosis inducing cytokines, such as
TGF-b. NK cells are capable of inducing target cell
apoptosis using all these primary killing mechanisms.
It would be of interest to study whether donor NK
cells might suppress the host alloreactive cells utilizing
any of these mechanisms.
In this article, we further investigated the affect of
allogeneic NK cells as suppressors of allo-responses
using an in vitro mixed lymphocyte response (MLR)
model system.We then demonstrated the mechanisms
NK cells using to suppress alloreactive CTL re-
sponses. Finally, using a nonmyeloablative allogeneic
BMT animal model, we showed that donor NK cells
can promote engraftment by suppressing host allor-
eactive responses. The results suggested that activated
donor NK cells could specifically suppress the host
reactive cells using multiple mechanisms, and they
provide a promising way to promote donor engraft-
ment during nonmyeloablative allogeneic BMT.MATERIALS AND METHODS
Animals
Female BALB/c (H2d), C57BL/6 (B6, H2b), and
C3H (H2k)mice were purchased from the Animal Pro-
duction Area of the National Cancer Institute (Freder-
ick, MD) and SLAC Animal Laboratory (Shanghai,
China). gld mice and pfp mice were purchased from
Jackson Laboratory (Bar Harbor, ME). Animals were
kept in specific pathogen-free conditions. All animal
protocols were approved at each of the 2 animal facil-
ities (University of Nevada, Reno, and SoochowUniversity). Mice were between 8 and 12 weeks of
age at the start of the experiments.Cell Lines and Reagents
P815 (H2d) murine lymphoblast-like mastocytoma
cell line and EL4 (H2b) murine T cell lymphoma cell
line were maintained in complete RPMI media. Anti-
Thy1.2 mAb (30H12) and rabbit-complement were
purchased from Cedarlane Laboratories (Burlington,
Ontario, Canada). All the other antibodies were pur-
chased from Becton-Dickinson and Company (BD,
Mountain View, CA). CFSE was purchased from
Molecular Probes (Eugene, OR).Cell Preparation
Bone marrow cell (BMC) suspensions were pre-
pared by gently releasing cells from the backbones,
femurs, and tibiae into Dulbecco’s phosphate-
buffered saline (PBS) solution with a mortar and
pestle, filtering through a mesh filter to remove partic-
ulates, and washing the cell suspensions twice. Spleen
cells were prepared by gently crushing the tissues to
release the cells. Preparations were filtered to remove
debris and washed twice in PBS before resuspending
in RF10 complete media (RPMI 1640 supplemented
with 10% FBS (Gemini Bio-Products, West Sacra-
mento, CA); 100 U/mL penicillin/streptomycin, 2
mM L-glutamine, 10 mM HEPES [N-2-hydroxye-
thylpiperazine-N-2-ethanesulfonic acid], 1 mM non-
essential amino acids, 1 mM sodium pyruvate, and
2.5 1025M2-ME). Cell counts were performed on
a Coulter Z1 cell counter (Coulter Electronics,
Hialeah, FL).Generation of ALAK Cells
The ALAK cells were generated according to the
method described before [16]. Briefly, splenocytes
and BMCs from C57BL/6 or BALB/c mice were
depleted of T cells by treatment with anti-Thy1.2
mAb (30H12) and rabbit-complement (Cedarlane
Laboratories). T cell-depleted samples were cultured
in RF10 complete medium (RPMI 1640 supplemented
with 10% FBS (Gemini Bio-Products); 100 U/mL
penicillin/streptomycin, 2 mM L-glutamine, 10 mM
HEPES [N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid], 1 mM nonessential amino acids, 1 mM
sodium pyruvate, and 2.5 1025 M2-ME containing
1000 IU/mL recombinant human IL-2 (rhIL-2;
Developmental Therapeutics Program, NCI, Be-
thesda, MD) at 1 to 2  106 cells/mL for 5 to 7 days
at 37C, 5% CO2. At day 3 or 4, nonadherent cells
were transferred to new flasks, and all cells were fed
with 50% conditioned medium, 50% new RF10 com-
plete medium, and rhIL-2. Only the adherent cells
were used for subsequent experiments.
774 Biol Blood Marrow Transplant 16:772-781, 2010B. Hu et al.Mixed Lymphocyte Response
To prepare responder C57BL/6 spleen cells,
spleen cells were made into single-cell suspension
and red blood cells were lysed. Stimulator cells were
prepared from single-cell suspensions of spleens
from BALB/c or C3H mice and irradiated (30 Gy).
Responders and stimulators were cultured at a final
concentration of 5  106/mL, pulsed with tritiated
thymidine (1 mCi/well) (Amersham Life Sciences,
Buckinghamshire, UK) 16 to 18 hours prior to harvest-
ing and counted on a b-plate reader (Packard Instru-
ments, Meriden, CT). Four individual wells were
analyzed per data point.
Cytotoxicity Assay
Alloreactive cytotoxic T cell activity was deter-
minedbyusing a chromium-release assaywith respond-
ing cells after a 72-hourMLR reaction or splenocytes 2
months afterBMT.P815orEL4cellswere labeledwith
51Cr (300 mCi) at 37C for 1 hour. They were then
washed and incubated at 104/well at different effector:
target ratios for 4 hours at 37C. Supernatants were
then harvested for gamma-counting. Maximum release
(M) was determined by adding Triton X-100 (1%) to
the targets. Spontaneous release (S) was determined
from targets cultured in the absence of effector cells.
The level of specific chromium release was calculated
as: % specific release 5 (counts – S)/(M – S), where
counts are the experimental chromium release in the
presence of effector cells.
CFSE Labeling and Flow Cytometry
In vitro activated NK cells were labeled with 1-2.5
mM carboxyfluorescein diacetate succinimidyl ester0
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Figure 1. H2d ALAK cells from BALB/c mice significantly suppress the (A) prol
allogeneic MLR stimulated with irradiated H2d splenocytes from BALB/C mice.
and BALB/c mice. The ALAK cell numberswere as indicated in the figure. The sa
P\.01.The data shown are the representative of four experiments.(CFSE; Molecular Probes, Eugene, OR) and added
into MLR reactions. After 3 days of culture, cells
were stained with anti-H2Kb PE and washed in ice-
cold PBS containing BSA (0.1%) and azide (0.01%)
and analyzed on a BD FACScan or Calibur using Cell-
Quest software (Becton-Dickinson).Animal Model of Nonmyeloablative BMT
Female C57BL/6 recipient mice received nonmye-
loablative doses (800–850 cGy) of total body irradia-
tion (TBI) from a 137Cesium source. Irradiation was
followed by the infusion of 1.0 or 1.5  106 BALB/c
BMCs i.v. with or without ALAK cells from BALB/c
mice (5 106 cells i.v.). Mice received gentamycin sul-
fate oral suspension (Ryen Pharma Co., China) in their
drinking water beginning 7 days before the transplant.
Mice were monitored and weighed weekly. The exper-
iments were performed 3 times with 5 to 7 mice per
group. Two months after BMT, flow cytometry anal-
ysis was performed to assess the donor engraftment by
labeling the splenocytes with anti-H2kd FITC and
anti-H2kb PE antibodies (Becton-Dickinson). The
alloreactivity against donor type antigens and killing
capacity to donor type tumor targets were also mea-
sured by MLR or cytotoxicity assay.RESULT
H2d ALAK Cells Can Significantly Suppress the
Proliferation and the Killing Capacity of H2b
Splenocytes in Allogeneic Primary MLR
To determine if allogeneic ALAK cells can sup-
press the host allo-responses, we set up an in vitro1:61:71
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Figure 2. Only the ALAK cells of stimulator origin can effectively suppress the allo-responses in the allogeneic MLR. The same number of H2d ALAK
cells and H2b ALAK cells were added to the H2b anti-H2d allogeneic MLR same as in Figure 1. The (A) proliferation and (B) killing capacity of H2b sple-
nocytes fromC57BL/6miceweremeasured at the end of the 3-day culture. (C) 1.25 105 H2d orH2k ALAK cells were added to H2b anti-H2dMLR. The
same numberof H2k ALAK cells was also added to H2b anti-H2kMLR. The proliferation of H2b splenocytes wasmeasured at the end of the 3-day culture.
(D) The killing capacity of H2b splenocytes was alsomeasured at the end of the 3-day culture. *Indicates P\.01. The data shown are the representative of
3 experiments.
Biol Blood Marrow Transplant 16:772-781, 2010 775Allogeneic NK Cells as Suppressors of Allo-responsesMLR system mimicking the allo-responses during the
allogeneic bone marrow transplantation. Allogeneic
NK cells of the stimulator origin were added into the
MLR reactions. After a 3-day culture, the proliferation
capacity of H2b splenocytes (responders) from
C57BL/6 mice was measured with 3H-thymidine
assay. H2d ALAK cells significantly suppressed the
proliferation of H2b splenocytes from C57BL/6 mice
in allogeneic MLR stimulated with irradiated H2d
splenocytes from BALB/c mice (Figure 1A). The ex-
tent of the suppressive effect was dependent on the
number of allogeneic ALAK cells added. The same
number of BALB/c splenocytes was also added as con-
trols, and they did not show any suppressive effect,
which suggested that the suppressive effect was caused
by NK cell activities, not just the increased number of
cells of H2d origin. The allogeneic activities of theH2b
responders were also measured by their killing capacity
of H2d tumor targets (P815). The H2b responders
were harvested after a 3-day MLR reaction mentioned
above and cocultured with 51Cr-labeled tumor targets
at different effector:target ratios for 4 hours. The
killing capacity was measured by 51Cr release in thesupernatants. Adding H2d ALAK cells during the
MLR reaction significantly suppressed the allogeneic
killing capacity of the H2b responders (Figure 1B).
The suppressive effect was also dose dependent. The
same number of BALB/c splenocytes did not show
any suppression but slightly increased the killing
activity of the responders (Figure 1B).
To determine whether the suppressive effect of the
allogeneic ALAK cells is dependent on their alloreac-
tivity, the same number of H2d ALAK cells (alloge-
neic) and H2b ALAK cells (syngeneic) were added to
the allogeneic MLR. The proliferation and killing
capacity of H2b responders were measured at the end
of the 3-day culture using the method mentioned
above (Figure 2). Comparing to the allogeneic ALAK
cells, the syngeneic ALAK cells had no suppressive
effect on the allogeneic responses. The third-party
H2k ALAK cells from C3H mice did not suppress
the anti-H2dMLR either, whereas they could suppress
the anti-H2k responses of the H2b responders
(Figure 2C). The H2k ALAK cells could slightly sup-
press the killing capacity of H2b responders in an
anti-H2dMLR only at a 50:1 ratio, but the suppressive
AC
B
Figure 3. The suppressive effect of allogeneic ALAK cells was not dependent on TGF-b secretion. Anti-TGF-b and the isotype control antibodies (35
mg/mL) were added to the allogeneic MLR described in Figure 1. (A) The levels of TGF-beta secreted in the MLR reaction with or without anti-TGF-beta
antibody were measured by ELISA. ND indicates not detected. (B) The proliferation of H2b splenocytes from C57BL/6 mice stimulated with irradiated
H2d splenocytes were measured at the end of the 3-day culture by 3H-thymidine incorporation assay. (C) The killing capacity of H2b splenocytes killing
H2d tumor cells (P815) were measured at the end of the 3-day culture by cytotoxicity assay. *Indicates P\.01. #Indicates P\.05. The data shown are the
representative of 3 experiments.
776 Biol Blood Marrow Transplant 16:772-781, 2010B. Hu et al.effect was a lot less comparing to H2d ALAK cells.
Therefore, only the ALAK cells of stimulator (donor)
origin could efficiently suppress the allogeneic
responses of the responders (host).
The Suppressive Effect of Allogeneic ALAKCells
Is Not Dependent on TGF-b Secretion
Todeterminewhether the suppressive effects of the
allogeneic ALAK cells were caused by the release of
TGF-b, anti-TGF-b blocking antibody and the isotype
control were added to the allogeneic MLR described
before (Figure 3). The production of TGF-b could be
detected in the assay and adding allogeneic ALAK cells
caused a slight increase, whereas the anti-TGF-bblock-
ing antibody significantly reduced it to the level that
could not be detected (Figure 3A). The proliferation
and killing capacity of alloreactive cells were measured
at the end of the 3-day culture (Figure 3B and C). The
suppressive effects of the allogeneic ALAK cells were
not affected by blocking the TGF-b activities, which
suggested that the suppressive effect of allogeneic NK
cells was not mediated by the TGF-b secretion.The Increased Number of H2d ALAK Cells Can
Cause the Diminishing of the H2b CTLs in the
Allogeneic MLR
The allogeneic NK cells could suppress the func-
tion of the alloreactive CTLs by direct killing. It would
be of interest to determine whether adding allogeneic
ALAK cells could cause the diminishing of the allor-
eactive CTLs in the allogeneic MLR. The CFSE-
labeled or unlabeled H2d ALAK cells were added to
the allogeneic MLR described before. It was shown
that the capacity of H2d ALAK cells to inhibit H2b
splenocytes killing H2d tumor target was not affected
byCFSE labeling (Figure 4A). Therefore, CFSE label-
ing could be used to identify the ALAK cells from the
alloreactive CTLs besides using MHC class I mole-
cules as markers in the flow cytometry assay. The num-
ber of CFSE2 H2b1PI2 cells was calculated as the
indication of live H2b CTLs left in the MLR culture,
and it was significantly decreased by adding CFSE-
labeled H2d ALAK cells (Figure 4B). However, adding
the CFSE-labeled H2d splenocytes did not signifi-
cantly change the number of CFSE2 H2b1PI2 cells
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Figure 4. The increased number of H2d ALAK cells could cause the diminishing of the H2b CTLs in the allogeneic MLR. The CFSE-labeled or unlabeled
H2d ALAK cells were added to the allogeneic MLR described in Figure 1. (A) The capacity of H2d ALAK cells to inhibit H2b splenocytes killing H2d tumor
target was not affected by CFSE labeling. (B) The number of live H2b CTLs left in the culture was significantly decreased by adding H2d ALAK cells.
*Indicates P\.01. The data shown are the representative of 3 experiments.
Biol Blood Marrow Transplant 16:772-781, 2010 777Allogeneic NK Cells as Suppressors of Allo-responsesin the culture. The data indicated that the mechanism
for allogeneic NK cells to suppress the allo-responses
could be direct killing of the alloreactive CTLs.The Suppressive Effect of Allogeneic ALAKCells
Is Partially Dependent on Perforin-Mediated
Killing Mechanism
To further study the killingmechanisms allogeneic
NK cells might be using to suppress the alloreactive
CTLs, the ALAK cells from wild-type C57BL/6
mice, gld mice (FasL mutant), and pfp mice (perforin
KO, both on C57BL/6 background) were used in the
MLR assay (Figure 5). The proliferation and killing
capacity of the alloreactive responders were measured
at the end of the 3-day culture. The ALAK cells from
the gld or pfpmice did not affect the proliferation sup-
pression of the alloreactive cells by the allogeneic
ALAK cells (Figure 5A). However, the ALAK cells
from pfp mice did not suppress the killing capacity of
the alloreactive CTLs as well as the ALAK cells from
the wild-type mice or the gld mice (P \ .05,
Figure 5B). The pfp ALAK cells were less effective
than gld and wild-type ALAK cells at both 50:1 and16:1 E:T ratio with addition of 2.5  105 or 1.25 
105 ALAK cells (P\ .05). It suggested that perforin-
mediated killing mechanism could be involved in the
direct killing of alloreactive CTLs by allogeneic NK
cells, but not the only mechanism during the process.Donor ALAK Cells Promote Donor
Engraftment in Nonmyeloablative Allogeneic
BMT
To demonstrate that donor ALAK cells could pro-
mote donor engraftment during nonmyeloablative
allogeneic BMT by suppressing the host alloreactive
responses, the ALAK cells from BALB/c mice were
infused into host C57BL/6 mice during nonmyeloa-
blative allogeneic BMT. Flow analysis demonstrated
that donor ALAK cell infusion (H2d NK, middle
panel) promoted donor engraftment dramatically
from 0.26% to 50.60% (Figure 6A). Syngeneic
ALAK cells (H2b NK, right panel) only slightly
increased donor engraftment to 2.01%. A summary
of the results from each experiment was shown in
Figure 6B. With 5 to 7 mice per group, all 3 experi-
ments showed similar results that donor ALAK cell
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Figure 5. The suppressive effect of allogeneic ALAK cells was partially dependent on perforin-mediated killing mechanism. The ALAK cells from wild
type C57BL/6 mice, gld mice, and pfp mice (both on C57BL/6 background) were used in the MLR assay. The (A) proliferation and (B) killing capacity of
H2d splenocytes from BALB/c mice were measured at the end of the 3-day culture. *Indicates P\.01. The data shown are the representative of 2 ex-
periments.
778 Biol Blood Marrow Transplant 16:772-781, 2010B. Hu et al.infusion dramatically promoted donor engraftment
during nonmyeloablative allogeneic BMT.
We further assessed the host alloreactive responses
after BMT by studying the proliferative responses to
donor type antigens and the killing capacity to donor
type tumor targets (Figure 7B and C). Two months af-
ter BMT and ALAK cell infusion, the host derived
CD41 and CD81 T cells were measured by flow cy-
tometry (Figure 7A). Most of the T cells were host de-
rived (H2b1) without donor ALAK cell infusion. Host
T cell percentage was reduced to around 60% when
donor ALAK cells were infused (H2d NK). Donor-
derived ALAK cell infusion during BMT significantly
suppressed the proliferation and IL-2 secretion in
response to alloantigen and the killing capacity of the
donor type tumor targets were also significantly
reduced. The alloreactivity to donor type antigen
was reduced to 25% to 30% with donor ALAK cell
infusion (H2d NK) compared to BMT alone and
syngeneic ALAK cell infusion (H2b NK). With about
60% host T cells remaining, the 25% to 30% alloreac-
tivity was not only because of less host T cells present,
but also the reduced alloreactivity of each cells. There-
fore, donor ALAK cells could promote engraftment bysuppressing host alloreactive responses in a nonmye-
loablative BMT model.DISCUSSION
In this article, we demonstrated that allogeneic
ALAK cells could suppress the host allo-responses in
an in vitro MLR system. The suppressive effects are
not only manifested by reduced proliferation, but
diminished killing capacity of the allo-responders.
These data reconcile with the early observations of en-
graftment promotions by donor NK cells in an alloge-
neic BMT. They provide insights to promoting
engraftment in not only nonmyeloablative BMT, but
also solid organ transplantation. The results further
elucidated the mechanism donor NK cells might be
using to suppress the host allo-responses. The inhibi-
tory effect of TGF-b on cytotoxic T cells is well
demonstrated before [17]. Our data showing that
anti-TGF-b antibody treatment did not affect the
suppression of allo-responses by allogeneic NK cells
suggest that TGF-b may not be the soluble factor
released by NK cells to mediate their suppressive
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Figure 6. Donor ALAK cells promoted donor engraftment in nonmyeloblative allogeneic BMT. The ALAK cells from BALB/c mice (H2d NK) were
infused into host C57BL/6 mice during nonmyeloblative allogeneic BMT. The ALAK cells from syngeneic C57BL/6 mice (H2b NK) were also infused
as control. (A) Flow analysis of the percent of donor engraftment 2 months after BMT. (B) Summary and statistical analysis of all the experiments.
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responders by allogeneic NK cells. Therefore, we ex-
amined the suppressive effects of the NK cells from
gld and pfp mice. The allogeneic ALAK cells from gld
mice suppressed the allo-responses as well as the
wild-type ALAK cells, whereas the ALAK cells from
pfp mice had reduced suppressive effects compared
with the wild-type ALAK cells. Therefore, the data
suggest that the allogeneic NK cells might be using
perforin-mediated killing mechanism to suppress the
allo-responses, but it is not the only mechanism for
their suppressive functions.
It has been well demonstrated that allogeneic NK
cells could potentially enhance the engraftment of
the allografts [7,18,19]. This could be because of the
veto effect of donor NK cells toward the host
alloreactive CTLs [9]. Although the veto effects on
CTLs could also be generated by other immune cells,
activated NK cells have been shown to be the domi-
nant veto cells shown by a TCR transgenic 2C mouse
model [20]. Activated CD41 T cells may also exert
veto effect on CTLs, but activated B cells, nonacti-
vated CD41, or NK cells are completely devoid of
veto activities. In a recent study, transferring ofallogeneic cytokine-induced killer (CIK) cells resulted
in minimal graft-versus-host disease (GVHD) with
retention of antitumor activity [21]. In that case, CIK
cells may exert cytotoxic activities on both syngeneic
and allogeneic targets. In the current studies, we exam-
ined the NK cell activities using the ex vivo IL-2-
activated ALAK cells. They are over 98% NK cells
and should perform as in vitro activated NK cells.
We showed that the donor NK cells could suppress
the host allo-responses. In the in vitro experiments,
third-party ALAK cells could not suppress the alloge-
neic MLR as well as the ALAK cells of stimulator
origin, suggesting that the alloreactive CTLs could
specifically recognize the ALAK cells of stimulator
origin, and then be eliminated by the ALAK cells
through veto mechanisms. ALAK cells could also be
activated by the NKG2D ligands expressed on the
alloreactive CTLs as well as the loss of inhibitory sig-
nals by the absence of self MHC class I molecules on
the alloreactive CTLs. The fact that third-party
ALAK cells could also suppress the killing capacity of
the responders suggests that multiple mechanisms
might be involved (ie, NKG2D). More experiments
are needed to demonstrate whether this suppressive
Figure 7. Donor ALAK cells could suppress host alloreactive responses in nonmyeloablative allogeneic BMT. The ALAK cells from BALB/c mice (H2d
NK) were infused into host C57BL/6 mice during nonmyeloablative allogeneic BMT. The ALAK cells from syngeneic C57BL/6 mice (H2b NK) were also
infused as control. (A) Percent of host derived CD41 and CD81 T cells (H2b T cells) out of total T cells 2 months after BMT. The host (B) proliferative
responses and IL-2 production responding to donor type antigens (irradiated BALB/c splenocytes) and (C) the killing capacity to donor type tumor
targets (P815 cells) were measured 2 months after BMT. Base control was the readout without alloantigen stimulation. *Indicates P\.01. The data
shown are the representative of 3 experiments.
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cells in vivo.
AlthoughTGF-bwas shown not a critical cytokine
for the suppressive effect of the allogeneic NK cells,
there might be other cytokines that could engage sup-
pressive effect on host allo-activities, such as IL-10. It
has been suggested that a subset of IL-10-secreting
NK cells can suppress the antigen-specific T cell re-
sponses [22]. Its suppressive effect is dependent on
IL-10 secretion. Whether allogeneic NK cells are
also predominantly IL-10-secreting cells and use the
same mechanism to suppress allo-responses need fur-
ther investigation.
NK cells can use a series of proteins to induce the
death of the target cells. Perforin is a critical compo-
nent in the cytotoxic granules to initiate apoptosis
pathway [16]. The interaction between Fas ligand
expressed by killer cells and the Fas receptor on the
target cell membrane was initially regarded as the
main mechanism of granule-independent killing
mechanism by CTL and NK cells [16,23]. In the
current studies, we investigated whether allogeneic
NK cells could be using one of these two killing
mechanisms to suppress host alloreactive CTLs. The
results indicated that granule-mediated killing
might be part of the mechanisms for allo-responsesuppression. However, apoptosis of target cells could
also be induced by several other members of the tumor
necrosis factor (TNF) ligand superfamily [24-26], such
as TNF-a, TRAIL, and TWEAK. TRAIL is widely
expressed on the surface of activated T and B cells,
NK cells, dendritic cells, and monocytes [27-29]. It
interacts with death receptor DR4 and DR5
[24,30,31] and cause TRAIL-induced apoptosis.
Therefore, the granule-mediated killing pathway
may not be the only mechanism for allogeneic NK
cell suppression. Our data also suggested that other
suppressive mechanisms may exist during the inhibi-
tion of allo-responses. The relevance of these mecha-
nisms in the nonmyeloablative BMT model would
need to be examined with further experiments using
functionally defective NK cells.
In conclusion, we demonstrate that activated allo-
geneic NK cells can specifically suppress the alloreac-
tive cells, inhibiting both their proliferation and killing
capacities. Granule-mediated killing might be part of
the suppressive mechanism, whereas the Fas-FasL
pathway and TGF-b signaling are not involved. These
specific suppressive effects of allogeneic NK cells pro-
vide a promising way to promote donor engraftment
without involving systemic and nonspecific suppres-
sion of the immune system.
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